Psychiatry and Neurology, Neurology · Norfolk, VA
NPI
1720088594
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6161 Kempsville Cir, Suite 315
Norfolk, VA, 23502
Phone (757) 461-5400
Groups this clinician bills Medicare through
Medicare paid, 2024
$346K
49,465 services
Medicare patients, 2024
517
Average age 68
Drug cost, 2024
$1.1M
4,777 prescriptions
Company payments, 2025
$11K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Firas Beitinjaneh was code J0174 (injection, lecanemab-irmb, 1 mg), 37,546 times for 20 patients. In total Firas Beitinjaneh billed 49,465 services in 48 codes, and Medicare paid $346K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-10-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0174 Injection, lecanemab-irmb, 1 mg | Office | 37,546 | 20 | $1.05 | $39K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 800 | 13 | $0.22 | $178 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 356 | 234 | $11.45 | $4,077 |
| 99213 Office E&M - Established | Office | 297 | 203 | $56.54 | $17K |
| 99214 Office E&M - Established | Office | 264 | 169 | $84.31 | $22K |
| 95819 Neurologic | Office | 93 | 92 | $331.22 | $31K |
| 96413 Chemotherapy Administration | Office | 91 | 53 | $97.62 | $8,884 |
| 95886 Electrical Nerve Conductivity | Office | 87 | 77 | $70.67 | $6,148 |
| 99215 Office E&M - Established | Office | 64 | 56 | $127.77 | $8,177 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 62 | 26 | $0.51 | $31.42 |
| 95909 Electrical Nerve Conductivity | Office | 29 | 29 | $87.67 | $2,542 |
| 95910 Electrical Nerve Conductivity | Office | 22 | 22 | $115.34 | $2,537 |
| 99204 Office E&M - New | Office | 19 | 19 | $64.18 | $1,220 |
| 99205 Office E&M - New | Office | 17 | 17 | $142.17 | $2,417 |
| 96415 Chemotherapy Administration | Office | 16 | 13 | $20.54 | $329 |
By year: 2022 $260K for 5,038 services; 2023 $227K for 10,051 services; 2024 $346K for 49,465 services.
Medicare prescription drug claims, 2024
In 2024, the drug Firas Beitinjaneh prescribed most often to Medicare patients was Levetiracetam, with 945 prescriptions and refills. In total Firas Beitinjaneh wrote 4,777 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levetiracetam Generic | 945 | 1,609 | 154 | $30K |
| Lamotrigine Generic | 374 | 568 | 51 | $5,463 |
| Zonisamide Generic | 330 | 526 | 49 | $15K |
| Lacosamide Generic | 285 | 350 | 35 | $29K |
| Topiramate Generic | 278 | 421 | 41 | $4,294 |
| Clobazam Generic | 183 | 211 | 18 | $28K |
| Phenobarbital Generic | 176 | 223 | 22 | $4,839 |
| Carbamazepine Er Carbamazepine | 173 | 245 | 24 | $27K |
| Oxcarbazepine Generic | 146 | 240 | 25 | $19K |
| Levetiracetam Er Levetiracetam | 127 | 212 | 22 | $10K |
| Carbamazepine Generic | 103 | 141 | 13 | $7,850 |
| Aptiom Eslicarbazepine Acetate | 99 | 109 | Under 11 | $166K |
| Lamotrigine Er Lamotrigine | 92 | 113 | Under 11 | $21K |
| Memantine Hcl Generic | 86 | 149 | 18 | $1,275 |
| Clonazepam Generic | 82 | 88 | 15 | $692 |
Brand drugs: 516 claims; generic drugs: 4,085 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Firas Beitinjaneh $11K ($11K in general payments such as food, travel and fees) from 14 companies. The largest payer was Eisai Inc. with $10K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.